Abstract
Very recently we had published a paper entitled ‘The Potential Development Sulfonylhydrazines for the Treatment of Alzheimer’s Disease’ [1]. Our paper was a development from an observation by others from 1997, where a remarkable remission in Dementia was observed in cancer patients following treatment with the chemotherapeutic agent BCNU (Carmustine, 1,3-Bis(2-chloroethyl)-1-nitrosourea) [2].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
